{
  "url": "https://finance.yahoo.com/news/certara-inc-nasdaq-cert-financials-105126278.html",
  "authorsByline": "Simply Wall St",
  "articleId": "c1e0659d3bd94933aaa355a4db732062",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/67ac92a32c5f9073ba3559a3e119b22a",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-08T10:51:26+00:00",
  "addDate": "2025-08-08T11:02:02.202689+00:00",
  "refreshDate": "2025-08-08T11:02:02.202691+00:00",
  "score": 1.0,
  "title": "Certara, Inc.'s (NASDAQ:CERT) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?",
  "description": "Certara's (NASDAQ:CERT) stock is up by a considerable 14% over the past week. However, we decided to pay attention to...",
  "content": "Certara's (NASDAQ:CERT) stock is up by a considerable 14% over the past week. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the company's financial health. In this article, we decided to focus on Certara's ROE.\n\nReturn on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.\n\nWe've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.\n\nThe formula for return on equity is:\n\nSo, based on the above formula, the ROE for Certara is:\n\n0.7% = US$8.0m \u00f7 US$1.1b (Based on the trailing twelve months to June 2025).\n\nThe 'return' is the profit over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.01 in profit.\n\nCheck out our latest analysis for Certara\n\nWhy Is ROE Important For Earnings Growth?\n\nSo far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or \"retains\" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.\n\nIt is quite clear that Certara's ROE is rather low. Even when compared to the industry average of 5.8%, the ROE figure is pretty disappointing. Accordingly, Certara's low net income growth of 3.2% over the past five years can possibly be explained by the low ROE amongst other factors.\n\nNext, on comparing with the industry net income growth, we found that Certara's reported growth was lower than the industry growth of 16% over the last few years, which is not something we like to see.\n\nEarnings growth is an important metric to consider when valuing a stock. It\u2019s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. Is CERT fairly valued? This infographic on the company's intrinsic value has everything you need to know.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138/past?blueprint=3972064&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138/valuation?blueprint=3972064&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/CERT",
    "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138?blueprint=3972064&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global?blueprint=3972064&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=dividend-forecast-yield-6pcnt"
  ],
  "labels": [
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "companies",
      "weight": 0.10703319
    },
    {
      "name": "Earnings Growth",
      "weight": 0.09842904
    },
    {
      "name": "Earnings growth",
      "weight": 0.09842904
    },
    {
      "name": "future growth",
      "weight": 0.09295228
    },
    {
      "name": "higher profit retention",
      "weight": 0.08251558
    },
    {
      "name": "Certara",
      "weight": 0.082060166
    },
    {
      "name": "Certaras low net income growth",
      "weight": 0.07613455
    },
    {
      "name": "ROE",
      "weight": 0.070907824
    },
    {
      "name": "profit",
      "weight": 0.07064025
    },
    {
      "name": "Current Share Price Momentum",
      "weight": 0.06678705
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "Stocks"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9853515625
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97607421875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.9677734375
    }
  ],
  "sentiment": {
    "positive": 0.11987305,
    "negative": 0.57421875,
    "neutral": 0.3059082
  },
  "summary": "Certara's (NASDAQ:CERT) stock has risen by 14% over the past week, but the company's financial fundamentals are not yet clear. The company's return on equity (ROE) is a key measure used to assess how efficiently a company's management is using its capital. ROE shows the profit each dollar generates with respect to its shareholder investments. For each $1 of shareholders' capital it has, the company makes $0.01 in profit. However, Certara's ROE is considered disappointing compared to the industry average of 5.8%. The company\u2019s low net income growth of 3.2% over five years can possibly be explained by the low ROE among other factors. Earnings growth is an important metric to consider when valuing a stock.",
  "shortSummary": "Certara's low ROE and low earnings growth are a significant contributor to its stock market rise, but investors may not know much about its financial stability due to low ROEs.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "5541097c71c74680b0837933ee807150",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138?blueprint=3972064&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "Certara (CERT) Stock Overview\nProvides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 1/6 |\n| Future Growth | 3/6 |\n| Past Performance | 2/6 |\n| Financial Health | 5/6 |\n| Dividends | 0/6 |\nCERT Community Fair Values\nSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.\nCertara, Inc. Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | US$11.26 |\n| 52 Week High | US$15.69 |\n| 52 Week Low | US$8.64 |\n| Beta | 1.42 |\n| 1 Month Change | -1.23% |\n| 3 Month Change | -6.01% |\n| 1 Year Change | -13.85% |\n| 3 Year Change | -44.23% |\n| 5 Year Change | n/a |\n| Change since IPO | -70.43% |\nRecent News & Updates\nRecent updates\nSome Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital\nAug 08Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)\nJul 18Is Certara (NASDAQ:CERT) Using Too Much Debt?\nJun 27FDA Phaseout And AI Integration Will Expand Biosimulation Demand\nRegulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around\nMay 07Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues\nApr 15Buy Certara After The FDA Announcement\nApr 11Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching\nMar 29Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly\nFeb 27Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up\nJan 11Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?\nDec 19Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return\nNov 15Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?\nOct 24Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly\nSep 20Certara: Still Awaiting Consistent Growth\nSep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate\nAug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price\nJul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital\nJun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?\nApr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk\nMar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)\nFeb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth\nJan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)\nDec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)\nOct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?\nSep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued\nAug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue\nAug 03Shareholder Returns\n| CERT | US Healthcare Services | US Market | |\n|---|---|---|---|\n| 7D | 14.4% | -2.5% | 0.2% |\n| 1Y | -13.8% | 32.1% | 19.9% |\nReturn vs Industry: CERT underperformed the US Healthcare Services industry which returned 34.4% over the past year.\nReturn vs Market: CERT underperformed the US Market which returned 22.4% over the past year.\nPrice Volatility\n| CERT volatility | |\n|---|---|\n| CERT Average Weekly Movement | 8.0% |\n| Healthcare Services Industry Average Movement | 8.6% |\n| Market Average Movement | 6.5% |\n| 10% most volatile stocks in US Market | 17.6% |\n| 10% least volatile stocks in US Market | 3.1% |\nStable Share Price: CERT has not had significant price volatility in the past 3 months compared to the US market.\nVolatility Over Time: CERT's weekly volatility (8%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2008 | 1,517 | Bill Feehery | www.certara.com |\nCertara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.\nCertara, Inc. Fundamentals Summary\n| CERT fundamental statistics | |\n|---|---|\n| Market cap | US$1.53b |\n| Earnings (TTM) | US$7.98m |\n| Revenue (TTM) | US$405.76m |\nIs CERT overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| CERT income statement (TTM) | |\n|---|---|\n| Revenue | US$405.76m |\n| Cost of Revenue | US$157.69m |\n| Gross Profit | US$248.07m |\n| Other Expenses | US$240.09m |\n| Earnings | US$7.98m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 0.05 |\n| Gross Margin | 61.14% |\n| Net Profit Margin | 1.97% |\n| Debt/Equity Ratio | 27.5% |\nHow did CERT perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/07 07:31 |\n| End of Day Share Price | 2025/08/07 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCertara, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Joseph Vruwink | Baird |\n| Luke Sergott | Barclays |\n| Andrew Moss | BofA Global Research |"
    },
    {
      "url": "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138/valuation?blueprint=3972064&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Is CERT undervalued compared to its fair value, analyst forecasts and its price relative to the market?\nValuation Score\n1/6\nValuation Score 1/6\nBelow Fair Value\nSignificantly Below Fair Value\nPrice-To-Sales vs Peers\nPrice-To-Sales vs Industry\nPrice-To-Sales vs Fair Ratio\nAnalyst Forecast\nShare Price vs Fair Value\nWhat is the Fair Price of CERT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.\nDiscounted Cash Flow\nSimply Wall St\nUS$10.89\nFair Value\n3.4% overvalued intrinsic discount\n9\nNumber of Analysts\nBelow Fair Value: CERT ($11.26) is trading above our estimate of fair value ($10.89)\nSignificantly Below Fair Value: CERT is trading above our estimate of fair value.\nKey Valuation Metric\nWhich metric is best to use when looking at relative valuation for CERT?\nKey metric: As CERT is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.\nThe above table shows the Price to Sales ratio for CERT. This is calculated by dividing CERT's market cap by their current\nrevenue.\nWhat is CERT's PS Ratio?\nPS Ratio\n4.5x\nSales\nUS$405.76m\nMarket Cap\nUS$1.53b\nCERT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.\nPrice-To-Sales vs Industry: CERT is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Healthcare Services industry average (2.6x).\nPrice to Sales Ratio vs Fair Ratio\nWhat is CERT's PS Ratio\ncompared to its\nFair PS Ratio?\nThis is the expected PS Ratio taking into\naccount the company's forecast earnings growth, profit margins\nand other risk factors.\nCERT PS Ratio vs Fair Ratio.\nFair Ratio\nCurrent PS Ratio\n4.5x\nFair PS Ratio\n2x\nPrice-To-Sales vs Fair Ratio: CERT is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (2x).\nAnalyst Price Targets\nWhat is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?\nThe above table shows the analyst CERT forecast and predictions for the stock price in 12 month\u2019s time.\nDate\nShare Price\nAverage 1Y Price Target\nDispersion\nHigh\nLow\n1Y Actual price\nAnalysts\nCurrent\nUS$11.26\nUS$14.44\n+28.28%\n9.44%\nUS$16.00\nUS$11.50\nn/a\n9\nAug \u201926\nUS$9.54\nUS$15.22\n+59.56%\n11.18%\nUS$18.00\nUS$13.00\nn/a\n9\nJul \u201926\nUS$11.52\nUS$15.78\n+36.96%\n10.78%\nUS$18.00\nUS$13.00\nn/a\n9\nJun \u201926\nUS$11.36\nUS$15.78\n+38.89%\n10.78%\nUS$18.00\nUS$13.00\nn/a\n9\nMay \u201926\nUS$13.29\nUS$15.44\n+16.21%\n14.43%\nUS$18.00\nUS$11.00\nn/a\n9\nApr \u201926\nUS$9.87\nUS$14.44\n+46.35%\n11.47%\nUS$17.00\nUS$12.00\nn/a\n9\nMar \u201926\nUS$11.98\nUS$14.70\n+22.70%\n11.90%\nUS$17.00\nUS$12.00\nn/a\n10\nFeb \u201926\nUS$14.23\nUS$14.17\n-0.45%\n12.23%\nUS$17.00\nUS$12.00\nn/a\n9\nJan \u201926\nUS$10.65\nUS$14.28\n+34.06%\n12.69%\nUS$17.00\nUS$12.00\nn/a\n9\nDec \u201925\nUS$11.21\nUS$14.28\n+27.37%\n12.69%\nUS$17.00\nUS$12.00\nn/a\n9\nNov \u201925\nUS$10.25\nUS$16.28\n+58.81%\n12.04%\nUS$20.00\nUS$13.00\nn/a\n9\nOct \u201925\nUS$11.35\nUS$17.17\n+51.25%\n11.49%\nUS$21.00\nUS$15.00\nn/a\n9\nSep \u201925\nUS$12.25\nUS$17.17\n+40.14%\n11.49%\nUS$21.00\nUS$15.00\nn/a\n9\nAug \u201925\nUS$15.64\nUS$18.83\n+20.42%\n11.74%\nUS$21.00\nUS$15.50\nUS$9.54\n9\nJul \u201925\nUS$13.64\nUS$19.50\n+42.96%\n11.84%\nUS$23.00\nUS$15.50\nUS$11.52\n9\nJun \u201925\nUS$16.95\nUS$19.72\n+16.36%\n10.36%\nUS$23.00\nUS$15.50\nUS$11.36\n9\nMay \u201925\nUS$17.30\nUS$19.74\n+14.10%\n9.82%\nUS$23.00\nUS$15.50\nUS$13.29\n10\nApr \u201925\nUS$18.00\nUS$19.38\n+7.65%\n8.73%\nUS$21.00\nUS$15.50\nUS$9.87\n9\nMar \u201925\nUS$18.30\nUS$19.31\n+5.53%\n9.24%\nUS$21.00\nUS$15.50\nUS$11.98\n8\nFeb \u201925\nUS$16.57\nUS$18.57\n+12.08%\n12.50%\nUS$21.00\nUS$14.00\nUS$14.23\n7\nJan \u201925\nUS$17.59\nUS$18.29\n+3.96%\n13.62%\nUS$21.00\nUS$14.00\nUS$10.65\n7\nDec \u201924\nUS$14.64\nUS$17.14\n+17.10%\n12.64%\nUS$21.00\nUS$14.00\nUS$11.21\n7\nNov \u201924\nUS$12.35\nUS$18.57\n+50.38%\n9.48%\nUS$21.00\nUS$16.00\nUS$10.25\n7\nOct \u201924\nUS$14.54\nUS$19.14\n+31.66%\n13.52%\nUS$24.00\nUS$16.00\nUS$11.35\n7\nSep \u201924\nUS$16.48\nUS$19.38\n+17.57%\n12.89%\nUS$24.00\nUS$16.00\nUS$12.25\n8\nAug \u201924\nUS$19.10\nUS$23.31\n+22.05%\n13.60%\nUS$27.00\nUS$18.00\nUS$15.64\n8\nAnalystConsensusTarget\nConsensus Narrative from 9 Analysts\nUS$14.44\nFair Value\n22.0% undervalued intrinsic discount\n9\nNumber of Analysts\nAnalyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.\nDiscover undervalued companies\n7D\n1Y\n7D\n1Y\n7D\n1Y\nCompany Analysis and Financial Data Status\nData\nLast Updated (UTC time)\nCompany Analysis\n2025/08/07 07:31\nEnd of Day Share Price\n2025/08/07 00:00\nEarnings\n2025/06/30\nAnnual Earnings\n2024/12/31\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCertara, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day."
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global?blueprint=3972064&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=dividend-forecast-yield-6pcnt",
      "text": "Results\n21\nThese stocks are forecast to deliver over a 6% dividend yield next year. Their dividend payments are well covered by cash flows and they have been growing steadily. Perfect for income-focused investors seeking robust returns.\n21 companies\nColumbia Banking System\nMarket Cap: US$5.0b\nOperates as the Bank holding company of Umpqua Bank that provides banking, private banking, mortgage, and other financial services in the United States.\nCOLB\nUS$23.65\n7D\n-0.6%\n1Y\n0.8%\nOmega Healthcare Investors\nMarket Cap: US$12.3b\nOmega Healthcare Investors, Inc. ist ein Real Estate Investment Trust (\"REIT\"), der Finanzierungen und Kapital f\u00fcr die langfristige Gesundheitsbranche bereitstellt, wobei der Schwerpunkt auf Einrichtungen f\u00fcr qualifizierte Pflege und betreutes Wohnen in den Vereinigten Staaten und im Vereinigten K\u00f6nigreich liegt.\nOHI\nUS$40.13\n7D\n3.2%\n1Y\n7.8%\nFlowers Foods\nMarket Cap: US$3.4b\nFlowers Foods, Inc. produziert und vermarktet verpackte Backwaren in den Vereinigten Staaten.\nFLO\nUS$16.26\n7D\n2.6%\n1Y\n-28.5%\nVerizon Communications\nMarket Cap: US$178.6b\nVerizon Communications Inc. bietet \u00fcber seine Tochtergesellschaften Kommunikations-, Technologie-, Informations- und Unterhaltungsprodukte und -dienste f\u00fcr Verbraucher, Unternehmen und staatliche Einrichtungen weltweit an.\nVZ\nUS$42.95\n7D\n0.4%\n1Y\n6.0%\nCitizens & Northern\nMarket Cap: US$287.8m\nDie Citizens & Northern Corporation ist die Bankholdinggesellschaft der Citizens & Northern Bank, die verschiedene Bank- und damit verbundene Dienstleistungen f\u00fcr Privat- und Firmenkunden anbietet.\nCZNC\nUS$18.39\n7D\n-3.3%\n1Y\n-2.2%\nHimax Technologies\nMarket Cap: US$1.5b\nHimax Technologies, Inc. ist ein fabrikloses Halbleiterunternehmen, das in China, Taiwan, Korea, Japan, den Vereinigten Staaten und international Technologien zur Verarbeitung von Bildschirmen anbietet.\nHIMX\nUS$7.16\n7D\n-19.2%\n1Y\n25.2%\nLCNB\nMarket Cap: US$205.5m\nDie LCNB Corp. ist die Finanzholding der LCNB National Bank, die in den Vereinigten Staaten Bankdienstleistungen anbietet.\nLCNB\nUS$14.32\n7D\n-3.0%\n1Y\n2.4%\nConagra Brands\nMarket Cap: US$9.1b\nConagra Brands, Inc. ist zusammen mit seinen Tochtergesellschaften vor allem in den Vereinigten Staaten als Lebensmittelhersteller f\u00fcr Konsumg\u00fcter t\u00e4tig.\nCAG\nUS$19.25\n7D\n5.4%\n1Y\n-36.5%\nBrookline Bancorp\nMarket Cap: US$906.2m\nBrookline Bancorp, Inc. ist als Bankholdinggesellschaft f\u00fcr die Brookline Bank t\u00e4tig, die Produkte und Dienstleistungen f\u00fcr Firmen-, Gesch\u00e4fts- und Privatkunden in den Vereinigten Staaten anbietet.\nBRKL\nUS$10.08\n7D\n-2.3%\n1Y\n4.9%\nArtisan Partners Asset Management\nMarket Cap: US$3.7b\nArtisan Partners Asset Management Inc. ist ein b\u00f6rsennotierter Verm\u00f6gensverwalter.\nAPAM\nUS$45.26\n7D\n0.02%\n1Y\n17.0%\nTFS Financial\nMarket Cap: US$3.5b\nDie TFS Financial Corporation bietet \u00fcber ihre Tochtergesellschaften Bankdienstleistungen f\u00fcr Privatkunden in den Vereinigten Staaten an.\nTFSL\nUS$12.68\n7D\n-3.3%\n1Y\n-2.9%\nXP\nMarket Cap: US$9.1b\nXP Inc. bietet Finanzprodukte und -dienstleistungen in Brasilien an.\nXP\nUS$17.34\n7D\n7.4%\n1Y\n-0.6%\nUnited Parcel Service\nMarket Cap: US$73.1b\nUnited Parcel Service, Inc. ist ein Paketzustell- und Logistikdienstleister, der Transport- und Zustelldienste anbietet.\nUPS\nUS$86.49\n7D\n0.4%\n1Y\n-31.5%\nBanco Latinoamericano de Comercio Exterior S. A\nMarket Cap: US$1.5b\nBanco Latinoamericano de Comercio Exterior, S.\nBLX\nUS$42.45\n7D\n6.2%\n1Y\n47.7%\nBuckle\nMarket Cap: US$2.6b\nThe Buckle, Inc. vertreibt in den Vereinigten Staaten unter den Marken Buckle und Buckle Youth Freizeitkleidung, Schuhe und Accessoires f\u00fcr M\u00e4nner, Frauen und Kinder.\nBKE\nUS$52.70\n7D\n6.7%\n1Y\n29.9%\nCricut\nMarket Cap: US$1.2b\nCricut, Inc. entwickelt, vermarktet und vertreibt eine Kreativit\u00e4tsplattform, die es Nutzern erm\u00f6glicht, Ideen in professionell aussehende, handgefertigte Produkte zu verwandeln, in den Vereinigten Staaten, Kanada, Gro\u00dfbritannien, Irland, Australien, Neuseeland, Westeuropa, dem Nahen Osten, Lateinamerika, S\u00fcdafrika und Asien.\nCRCT\nUS$5.69\n7D\n16.1%\n1Y\n-12.5%\nGlobal Ship Lease\nMarket Cap: US$1.1b\nGlobal Ship Lease, Inc. ist zusammen mit seinen Tochtergesellschaften im Besitz von Containerschiffen und verchartert diese zu festen Raten an Containerschifffahrtsunternehmen weltweit.\nGSL\nUS$30.09\n7D\n5.5%\n1Y\n10.5%\nMacy's\nMarket Cap: US$3.3b\nMacy's, Inc. ist ein Omnichannel-Einzelhandelsunternehmen, das in den Vereinigten Staaten Gesch\u00e4fte, Websites und mobile Anwendungen betreibt.\nM\nUS$12.11\n7D\n-4.1%\n1Y\n-23.2%\nOxford Industries\nMarket Cap: US$579.2m\nOxford Industries, Inc. ist ein Bekleidungsunternehmen, das Lifestyle-Produkte entwickelt, beschafft, vermarktet und weltweit vertreibt.\nOXM\nUS$38.74\n7D\n1.5%\n1Y\n-58.8%\nMarket Cap: US$2.4b\nDie Weibo Corporation betreibt \u00fcber ihre Tochtergesellschaften eine Social-Media-Plattform, auf der Menschen in der Volksrepublik China Inhalte erstellen, entdecken und verbreiten k\u00f6nnen.\nWB\nUS$9.72\n7D\n0.8%\n1Y\n24.0%\nSila Realty Trust\nMarket Cap: US$1.4b\nSila Realty Trust, Inc. mit Hauptsitz in Tampa, Florida, ist ein Net Lease Real Estate Investment Trust mit strategischem Schwerpunkt auf Investitionen in den wachsenden und widerstandsf\u00e4higen Gesundheitssektor.\nSILA\nUS$25.23\n7D\n3.2%\n1Y\n14.6%"
    },
    {
      "url": "https://simplywall.st/company/id/A02AFEDF-872D-4D47-8815-21DF46DA4138/past?blueprint=3972064&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Certara Past Earnings Performance\nPast criteria checks 2/6\nCertara has been growing earnings at an average annual rate of 3.2%, while the Healthcare Services industry saw earnings growing at 24.4% annually. Revenues have been growing at an average rate of 11% per year. Certara's return on equity is 0.7%, and it has net margins of 2%.\nKey information\n3.16%\nEarnings growth rate\n6.78%\nEPS growth rate\n| Healthcare Services Industry Growth | 1.72% |\n| Revenue growth rate | 10.99% |\n| Return on equity | 0.75% |\n| Net Margin | 1.97% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nRecent updates\nSome Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital\nAug 08Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)\nJul 18Is Certara (NASDAQ:CERT) Using Too Much Debt?\nJun 27FDA Phaseout And AI Integration Will Expand Biosimulation Demand\nRegulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around\nMay 07Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues\nApr 15Buy Certara After The FDA Announcement\nApr 11Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching\nMar 29Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly\nFeb 27Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up\nJan 11Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?\nDec 19Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return\nNov 15Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?\nOct 24Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly\nSep 20Certara: Still Awaiting Consistent Growth\nSep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate\nAug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price\nJul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital\nJun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?\nApr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk\nMar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)\nFeb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth\nJan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)\nDec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)\nOct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?\nSep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued\nAug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue\nAug 03Revenue & Expenses Breakdown\nHow Certara makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 406 | 8 | 121 | 36 |\n| 31 Mar 25 | 394 | -3 | 124 | 36 |\n| 31 Dec 24 | 385 | -12 | 121 | 37 |\n| 30 Sep 24 | 373 | -31 | 117 | 37 |\n| 30 Jun 24 | 364 | -79 | 112 | 38 |\n| 31 Mar 24 | 361 | -61 | 95 | 37 |\n| 31 Dec 23 | 354 | -55 | 94 | 34 |\n| 30 Sep 23 | 353 | -34 | 94 | 33 |\n| 30 Jun 23 | 352 | 19 | 93 | 30 |\n| 31 Mar 23 | 344 | 14 | 100 | 30 |\n| 31 Dec 22 | 336 | 15 | 97 | 28 |\n| 30 Sep 22 | 324 | -4 | 87 | 28 |\n| 30 Jun 22 | 314 | -10 | 95 | 26 |\n| 31 Mar 22 | 301 | -12 | 93 | 23 |\n| 31 Dec 21 | 286 | -13 | 88 | 20 |\n| 30 Sep 21 | 275 | -58 | 134 | 24 |\n| 30 Jun 21 | 262 | -55 | 120 | 23 |\n| 31 Mar 21 | 253 | -49 | 111 | 21 |\n| 31 Dec 20 | 244 | -49 | 106 | 20 |\n| 30 Sep 20 | 233 | -1 | 60 | 12 |\n| 30 Jun 20 | 226 | 1 | 58 | 12 |\n| 31 Mar 20 | 215 | -5 | 57 | 12 |\n| 31 Dec 19 | 209 | -9 | 53 | 12 |\n| 31 Dec 18 | 164 | -33 | 51 | 10 |\nQuality Earnings: CERT has a large one-off loss of $10.5M impacting its last 12 months of financial results to 30th June, 2025.\nGrowing Profit Margin: CERT became profitable in the past.\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: CERT has become profitable over the past 5 years, growing earnings by 3.2% per year.\nAccelerating Growth: CERT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.\nEarnings vs Industry: CERT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.9%).\nReturn on Equity\nHigh ROE: CERT's Return on Equity (0.7%) is considered low.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/07 07:31 |\n| End of Day Share Price | 2025/08/07 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCertara, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Joseph Vruwink | Baird |\n| Luke Sergott | Barclays |\n| Andrew Moss | BofA Global Research |"
    }
  ],
  "argos_summary": "Certara's stock has risen 14% in the past week, but its fundamentals reveal a concerning financial health, particularly highlighted by a low return on equity (ROE) of 0.7%, significantly below the industry average of 5.8%. This low ROE correlates with Certara's modest net income growth of 3.2% over the past five years, which is also underwhelming compared to the industry growth rate of 16%. Investors may need to consider these factors when evaluating the stock's future potential.",
  "argos_id": "PY0KG9KI6"
}